Forty thousand elective procedures are performed in the United States each year to repair abdominal aortic aneurysm (AAA), resulting in ϳ1250 perioperative deaths. 1 The introduction of endovascular repair in the 1990s as a less invasive alternative to open repair therefore generated considerable interest, 2 and several randomized trials were undertaken to compare the two procedures. Although these trials have generally reported reduced perioperative mortality with endovascular repair, midterm and long-term outcomes have been similar for the two procedures. [3] [4] [5] This similarity increases the need for an accurate comparison of costs, particularly in view of the high cost of endovascular grafts, which has led most previous authors to conclude that endovascular repair is not cost-effective. 3, 6, 7 The Department of Veterans Affairs (VA) Open Versus Endovascular Repair (OVER) trial recently reported a comparison of clinical outcomes of the two procedures at 2 years after randomization. 5 We report here, for the same 2-year period, total health care costs and comparative costeffectiveness of elective open and endovascular repair of AAA in the VA OVER trial.
METHODS
Patients and clinical outcomes. The general methods and 2-year clinical outcomes of the OVER trial have been reported previously. 5 (2) an associated iliac aneurysm with a maximum diameter of Ն3.0 cm, or (3) a maximum diameter of Ն4.5 cm plus rapid enlargement or saccular morphology. Patients also had to be candidates for both procedures and were excluded if they had undergone previous abdominal aortic surgery, needed urgent repair, or were unable or unwilling to give informed consent or follow the protocol. Follow-up visits were scheduled 1 month after aneurysm repair, 6 and 12 months after enrollment, and then yearly. Patients were called monthly during the first 14 months after repair and then annually midway between study visits to identify outcomes and were asked to log all health care visits. All follow-up visits after endovascular repair included a computed tomography scan and plain radiography of the abdomen; after open repair, only a computed tomography scan at 1 year was specified, a difference intended to reflect usual clinical practice.
The trial was designed to have 80% power to detect a 25% relative reduction in death after 9 years. 5 No additional power calculations were conducted for the cost analysis, for which the primary outcome was mean total health care cost per life-year and per quality-adjusted life-year (QALY). As described in the previous report, 5 the protocol originally specified publication of 1-year results when available on all patients, amended to include follow-up data to 2 years after randomization as of October 15, 2008 . Mean follow-up was 1.8 years, and 80% of patients had completed 2 years of follow-up or had died Յ2 years. Perioperative mortality (30 days or inpatient) was lower for endovascular repair (0.5% vs 3.0%; P ϭ .004), but the difference in mortality at 2 years (7.0% vs 9.8%) was not statistically significant (P ϭ .13), nor was the difference between the two groups in major morbidity, procedure failure, secondary therapeutic procedures, aneurysm-related hospitalizations, or health-related quality of life (QOL).
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Assessment of utilization and costs. The clinical trial database of OVER patients was linked to national VA and Medicare databases to obtain information on health care utilization and cost. All health care costs were included and were adjusted to 2008 U.S. dollars with the Consumer Price Index. Costs are estimated from the perspective of all health care providers (ie, the VA and private-sector providers).
To obtain the level of detail needed for comparison, costs for the hospitalizations during which the AAA repair operation was performed were obtained from the VA Decision Support System (DSS) National Data Extracts. 8 The DSS extracts information from VA accounting and payroll system and combines this with workload information from patient care and administrative departments to produce estimates of cost. Costs are compiled from intermediate products that make up the encounter, such as a radiologic test, a day in a ward, or a 15-minute block of time in an operating room. A hospital stay is divided into segments according to the bed section, such as medical care, a surgical ward, or a unit providing long-term care.
Within each bed section, DSS allocates costs among six mutually exclusive categories: surgery, nursing, laboratory, radiology, pharmacy, and other. The "surgery" cost category could thus be included whether or not a patient is on the surgery bed section and encompasses preoperative care, the operating suite, and the recovery room on the day of surgery. "Nursing" includes the operating costs of regular acute-care wards and long-term care units, excluding physician costs. The category "other" includes daily physician costs, ward clerks, respiratory therapy, dietetics, and social work, among others. Each of these six categories includes fixed direct costs that are directly attributable to that category but incurred regardless of the volume of services provided and fixed indirect costs, including overhead departments such as housekeeping, engineering, and administration, allocated by formulas derived from intermediate product use.
Graft components used for each patient were recorded on OVER study forms, and prices were obtained from the VA National Patient Prosthetics Database. If the price for a specific component was not available, we used the price of a component in the same class from the same manufacturer. Costs relating to the first procedure at which the AAA repair was completed were compared. Prior aborted procedures and subsequent procedures occurring during other hospitalizations were included in overall costs but not in the AAA repair hospitalization cost.
All other VA utilization data, including other hospital stays, outpatient visits, contract care, and outpatient medications acquired from VA, were obtained from the VA Medical SAS Inpatient and Outpatient Data sets extracted from the National Patient Care Database, which captures all utilization from the electronic record system of local VA medical centers, 9, 10 and also from the Fee Basis files, which report care provided to VA patients by contract providers outside of VA facilities.
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The costs for VA utilization other than the hospitalization for the AAA procedure were obtained from the VA Health Economics Resource Center (HERC) average cost data sets. [12] [13] [14] The average cost data sets are more directly comparable to the costing used for non-VA health care utilization at Medicare-financed facilities than the DSS method used for the AAA repair hospitalization. In the HERC average cost data sets, the costs of acute medical and surgical hospital care are obtained using an econometric cost function that was developed by modeling costs from Medicare claims data as a function of Diagnosis Related Group weights, length of stay, and demographic and other clinical information.
The Medicare costs used in this cost function were derived from charges in the Medicare claims data and adjusted to costs using cost-to-charge ratios from cost reports that facilities submit to the Center for Medicare and Medicaid Services. 12 The resulting cost function provides an estimate of the relationship between inpatient costs and characteristics of the patient and admission such as age, sex, Diagnosis Related Group weights, and length of stay. These relationships are then applied to information in the VA Medical SAS Inpatient Datasets 9 to estimate VA acute medical and surgical costs.
Costs for nonacute hospital stays (eg, rehabilitation, mental health, and long-term care) were estimated by calculating an average cost per day for each type of care from the DSS National Data Extracts and then multiplying by length of stay. Costs for VA outpatient visits were based on reimbursement rates of Medicare and other health care payers. Costs for prescriptions obtained from the VA were based on the VA's acquisition and dispensing costs from the VA DSS National Data Extracts Pharmacy data sets. 15 Non-VA health care utilization was obtained from Medicare claims data (available for 67% of the patientmonths in the study period) and from patient self-reported data verified with billing data from the facilities where care was received. Costs were estimated by multiplying the health care charges in the Medicare claims or billing data by the hospital-specific cost-to-charge ratios obtained from cost reports submitted to Medicare annually. 16 For the self-reported inpatient admissions or nursing home stays for which we did not have corresponding billing information, we estimated costs based on the self-reported length of stay and the available billing information. We calculated a cost per day from the available billing data and then multiplied the cost per day by the self-reported length of stay to estimate a cost for that health care encounter.
Assessment of effectiveness. Effectiveness was measured in life-years after randomization and in QALYs, which incorporate health-related QOL and medical outcomes into a single measure. 16 Health-related QOL was assessed using the EQ-5D (EuroQol, Rotterdam, The Netherlands), a brief questionnaire designed for this purpose. To compute QALYs, EQ-5D index scores obtained at baseline, 6 months, and annually were converted into utility weights based on U.S. population preferences. 17 These utility weights range from Ϫ0.11 for the worst EQ-5D index score to 1.0 for the best on a scale where 0.0 ϭ death and 1.0 ϭ perfect health. When values were missing, the most recent score was used. The utility weights were connected with straight lines (and connected to 0.0 for the date of death) to construct the quality-adjusted survival curve. QALYs were computed from the area under the curve, calculated using the trapezoid rule.
Analysis. We compared cost and effectiveness (measured in life-years and QALYs) between patients randomized to endovascular and open repair on an intention-totreat basis, regardless of the occurrence or type of the actual AAA repair. We calculated 95% confidence intervals (CIs) around differences in mean utilization and costs between patients randomized to endovascular or open repairs using bias-corrected accelerated bootstrapping to adjust for skewing in the data. 18 Means were used, as recommended by guidelines, 19 because total costs for the patient group can be derived from them to estimate budgets. Medians are also shown. P values were estimated from the bootstrapping procedure and t tests. Because of multiple comparisons, marginal values should be interpreted with caution. We estimated QALYs at 2 years after randomization and calculated the 95% CI around the difference in mean QALYs using the bootstrap method. The difference in mean QALYs was adjusted for baseline EQ-5D utility scores using regression methods. 20 P values for life-years were obtained from t tests, and P values for QALYs were obtained from the regression analysis. As is standard in cost-effectiveness analyses, we discounted costs, life-years, and QALYs at 3% per year starting with the date of randomization. 16 To assess the precision of our cost-effectiveness analysis, we used bootstrap methods to examine the distribution of the incremental cost (ie, mean total costs of the endovascular group minus mean total costs of the open repair group) and incremental effectiveness (ie, mean life-years or QALYs for the endovascular group minus mean life-years or QALYs for the open repair group) across regions of the cost-effectiveness plane. 7, 21 This method provides a means for quantifying the robustness of the cost-effectiveness analysis results across the four quadrants of the cost-effectiveness plane showing the relationship between differences in mean costs and mean effectiveness.
As a sensitivity analysis, we estimated costs using Kaplan-Meier sample average estimators, which account for censoring in estimating mean total health care costs. 22 The method involves dividing the study period into smaller time intervals, estimating the average costs over each interval for patients alive at the start of the interval, multiplying the average total cost in each interval by the Kaplan-Meier survival probability of being alive at the beginning of the interval, and calculating the mean total costs by summing these costs over the study period.
RESULTS
The mean cost of the hospital admission for the AAA procedure was lower for the endovascular repair group ($37,068) than for the open repair group ($42,970), for a difference of -$5901 (95% CI, -$12,135 to -$821; P ϭ .04; Table I ). The surgical procedure cost substantially more in the endovascular group ($23,618 vs $11,594; P Ͻ .001) because of the much higher costs of the grafts ($14,052 vs $1363; P Ͻ .001). However, patients in the endovascular group were hospitalized for less than half the number of days (mean, 5.0 vs 10.5 days; P Ͻ .001; Table  II ) and had shorter intensive care unit stays (mean, 1.9 vs 5.6 days; P Ͻ .001) during that admission. As a consequence, other components of the hospitalization for the AAA procedure were more costly for the open group, including nursing, pharmacy, and laboratory costs, which is also reflected in the fixed direct and indirect costs for these cost categories (as shown for nursing in Table I ).
Compared with the open group, the endovascular group had significantly more VA outpatient visits in the 30 days after the admission for the AAA procedure (Table II) and significantly higher costs related to VA outpatient visits in the 30 days after the AAA repair admission and from 30 days to 1 year, but differences in overall costs during these periods were not significant (Table III) Cost-effectiveness analysis. After 2 years of followup, mean life-years were 1.78 for the endovascular group and 1.74 for the open group (difference, 0.04; 95% CI, Ϫ0.03 to 0.09; P ϭ .29). Health-related QOL, as measured by the EQ-5D, did not differ significantly between the two groups at baseline, 6 months, 1 year, or 2 years (Table IV) . When this QOL information was combined with life years, the endovascular group had a mean of 1.462 QALYs, whereas the open group had 1.461 QALYs (difference adjusting for baseline EQ-5D score, 0.006; 95% CI, Ϫ0.038 to 0.052; P ϭ .78). With lower costs and more life-years, endovascular repair was the dominant strategy and so we did not calculate an incremental cost-effectiveness ratio (ie, the cost per life-year saved).
The bootstrap analysis to characterize the precision of our cost-effectiveness estimates, conducted by 2000 samplings (with replacement) of the 881 observations from trial participants, is plotted in the Fig. When effectiveness was measured in life-years, the bootstrap analyses indicated that there was a 70.9% probability of endovascular repair being less costly and more effective than open repair (Fig,  A) . When effectiveness was measured in QALYs, the probability that endovascular repair was less costly and more effective dropped to 51.4% (Fig, B) . The proportions of observations from the bootstrap analyses below the diagonal lines indicate the observations that would favor endovascular repair if the decision maker were willing to pay $50,000 or $100,000 per life-year or QALY. From these observations, if willing to pay $50,000, endovascular repair is preferred in 88.1% of observations using life-years and in 83.4% using QALYs, whereas if willing to pay $100,000, the proportions are 90.4% and 83.3%, respectively.
DISCUSSION
In this multicenter randomized trial, survival, QOL, and costs after 2 years were not significantly different between endovascular and open repair of AAA. The hospital admission for AAA repair was less expensive in the endovascular repair group, largely because of shorter hospital and intensive care length of stay, and despite the high cost of the endovascular grafts. Two-year costs apart from the hospital admission for the AAA procedure were nearly identical between the two groups.
Most previous studies have found endovascular repair to be a more expensive strategy despite the shorter hospital and intensive care length of stay. 3, 6, 7 Randomized trials are considered one of the most informative approaches to economic evaluation, 23 Second, open repair could have fared relatively worse in our study than in the European trials because the cost of a day in the hospital is substantially higher in the U.S. than in Europe, whereas the costs of endovascular grafts are more similar. 3, 7 Third, the VA cost-accounting methods used in our study, which include fixed direct and indirect costs, may capture costs of hospitalization more thoroughly than did the previous studies, again, causing open repair to fare worse.
Results similar to ours were obtained in a Swedish population-based study of 109 patients who underwent AAA repair in 2001 to 2005. 26 After a mean of 2.5 years, there was a nonsignificant trend toward lower AAA-associated costs with endovascular repair (€26,382) than with open repair (€29,786). This study was not randomized, however, and there were significant differences between the two groups at baseline. A Canadian study found nearly identical costs at 1 year between the two procedures in 192 high-risk patients undergoing repair from 2003 to 2005. 27 A literaturebased model developed for the U.K. National Institute for Health and Clinical Excellence in 2009 concluded that endovascular repair was likely to be more cost-effective than open repair in higher-risk patients. 28 Our study has several limitations: First, some costs that might seem to apply to only one group are distributed as fixed direct costs among all patients in both groups, such as disposable supplies (eg, guidewires, sheaths, sutures, cell-saving devices, balloons) and items bought for repeated use (eg, to equip an operating room or endovascular suite).
Second, the cost of some preoperative evaluations was not included because patients had to be candidates for both procedures before randomization. In some patients, this might have required more imaging than would otherwise have been used before open repair.
Third, although our study was intended to closely replicate usual practice in most respects, there were a few protocoldriven deviations that could distort costs, such as the required computed tomography scan 1 year after open repair.
Fourth, we did not collect QOL data between baseline and 6 months, a period during which some studies 29 have observed a transient difference favoring endovascular repair.
Fifth, our study was conducted at VA medical centers and used VA accounting methods and so our results may not directly apply to other populations (ie, women, of whom there were only 5 in our study) in other health care settings. However, our population is otherwise typical of patients with AAA, who are predominantly older men with a history of smoking. Furthermore, the VA is the largest integrated health care system in the U.S., providing care to Ͼ6 million veterans, 30 to whom our results are directly applicable. The accounting methods we used have been developed over more than a decade by economists at the VA Health Economics Resource Center, have been used in numerous federally funded economic studies, and may serve as a model for cost-accounting in other systems. Although it has been alleged at times that VA costs for care might be higher than costs for care obtained in non-VA health care, 31 the best evidence indicates that this is not the case. 32 The VA may be obtaining some items, such as medications and, in our study, endovascular grafts, at lower costs than non-VA users. In settings in which endovascular grafts costs are substantially different from the mean $14,052 per patient we observed, our findings may not apply. Finally, we reported all health care costs rather than only those related to AAA repair, which some might consider a limitation. In fact, assessment of all costs is the preferred method recommended by guidelines. 19 The trade-off is between dilution of the effect of the intervention when all costs are used vs errors introduced in attempting to identify intervention-related costs. Because this analysis was limited to 2 years and most of the costs were clearly intervention-related, dilution could be expected to be minimal, favoring our selection of all costs.
CONCLUSIONS
Endovascular repair represents an important advance in the treatment of AAA. Our findings show that endovascular repair is a cost-effective alternative to open repair in the U.S. VA health care system, at least in the first 2 years. Because some studies have found endovascular repair requires more late reinterventions than open repair, which could adversely affect long-term cost-effectiveness, it will be important to re-examine cost-effectiveness again at the end of our 9-year study. 
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